- Global Pharma News & Resources

Press Releases - 2020-04-27

Date Title Company
27-Apr-2020 MagForce AG: MagForce USA, Inc. has received FDA Approval to proceed with its Streamlined Trial Protocol for the next Stage of Pivotal U.S. Single-Arm Study for the Focal Ablation of Intermediate Risk Prostate Cancer with the NanoTherm Therapy System MagForce AG
27-Apr-2020 Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias Syndax Pharmaceuticals, Inc.
27-Apr-2020 BioPharmX Corporation Announces that its Special Stockholders' Meeting will now be held on Wednesday, May 13, 2020 at 10:00 AM eastern time BioPharmX Corporation
27-Apr-2020 MorphoSys and I-Mab Announce First Patient Dosed in Phase 3 Clinical Trial of MOR202/TJ202 in r/r Multiple Myeloma in Mainland ChinaMorphoSys AG: (news with additional features) MorphoSys AG
27-Apr-2020 Heidelberg Pharma AG Raises EUR 14.4 Million From Private Placement Heidelberg Pharma AG
27-Apr-2020 Heidelberg Pharma AG Plans Capital Increase to Fund Its ATAC Development Program Heidelberg Pharma AG
27-Apr-2020 FDA Warns Manufacturers and Retailers to Remove Certain E-cigarette Products Targeted to Youth from the Market U.S. Food and Drug Administration
27-Apr-2020 Photocure Regains Worldwide Rights of Hexvix Photocure
27-Apr-2020 New Player Cantourage Challenges Canopy Growth on Dronabinol Cannabis Monopoly in Europe Cantourage
27-Apr-2020 CerpassRx  and GoodRx Launches Employee Relief Program in response to COVID-19 CerpassRx
27-Apr-2020 Top-Level industry professionals to speak at Pain Therapeutics Conference in 2 weeks SMi Group
27-Apr-2020 Orgenesis completes acquisition of Tamir Biotechnology, Inc. assets including broad spectrum antiviral platform Orgenesis
27-Apr-2020 Six COVID-19 Patients Treated with RedHill’s Opaganib Under Compassionate Use Show Objective Clinical Improvement RedHill Biopharma
27-Apr-2020 Phase 3 trial of Libtayo® (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival Sanofi
27-Apr-2020 Sanofi and Regeneron provide update on U.S. Phase 2/3 adaptive-designed trial in hospitalized COVID-19 patients Sanofi
27-Apr-2020 ARTES Joins Global Combat against Corona ARTES Biotechnology
27-Apr-2020 Valo Therapeutics to Support Development of a Pan – Coronavirus Vaccine Valo Therapeutics
27-Apr-2020 Lokelma US label updated to include dosing guidance for the treatment of hyperkalaemia in patients with end-stage renal disease on haemodialysis Label update is based on data from Phase IIIb DIALIZE trial AstraZeneca
27-Apr-2020 Mental health care company COMPASS Pathways concludes successful Series B investment round $80m raised will further the development of psilocybin therapy COMPASS Pathways
27-Apr-2020 Research into medicinal cannabis for treatment of coronavirus ANANDA DEVELOPMENTS PLC